UK markets closed

RedHill Biopharma Ltd. (RDHL)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.4736-0.0083 (-1.72%)
At close: 04:00PM EDT
0.4705 -0.00 (-0.65%)
After hours: 07:06PM EDT

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv 6473921
972 3 541 3131

IndustryDrug Manufacturers - Specialty & Generic
Full-time employees53

Key executives

NameTitlePayExercisedYear born
Mr. Dror Ben-AsherCo-Founder, Chairman & CEO594.61kN/A1966
Mr. Razi IngberChief Financial Officer339.82kN/A1984
Mr. Gilead Raday MPhil, MScChief Operating Officer365.56kN/A1975
Mr. Adi FrishChief Corporate & Business Development Officer339.3kN/A1970
Mr. Rick D. ScruggsChief Commercial Officer, President of RedHill Biopharma Inc. & Director469.8kN/A1960
Ms. Alexandra OkmianSenior Business Development & Investor Relations ManagerN/AN/AN/A
Dr. Reza Fathi Ph.D.Senior Vice President of Research & Development299.29kN/A1955
Mr. Guy Goldberg J.D.Chief Business Officer338.13kN/A1976
Dr. June S. Almenoff FACP, M.D., Ph.D.Chief Medical OfficerN/AN/A1957
Ms. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Corporate governance

RedHill Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.